Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Regencell Bioscience Holdings Ltd(RGC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RGC
10/14/2026: RGC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Regencell Bioscience is a biotechnology firm that specializes in developing traditional Chinese medicine for infectious and neurocognitive conditions. The company's main strength lies in its proprietary formulations and focus on evidence-based research within a niche sector. Its primary growth opportunity hinges on successfully completing clinical trials to secure regulatory approval, which would validate its pipeline. However, significant risks include regulatory hurdles, intense competition from well-capitalized pharmaceutical giants, and the speculative nature of its early-stage business. The stock best suits risk-tolerant investors interested in alternative medicine development, and stakeholders should closely monitor clinical trial milestones and regulatory progress as key indicators of future viability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is in an early, speculative stage with high uncertainty regarding long-term revenue growth. |
| Momentum investor | Mixed fit | The stock can exhibit high volatility, but it lacks the consistent upward trend usually sought by momentum investors unless specific positive clinical news breaks. |
| Value investor | Weak fit | The company lacks stable earnings or dividends that would appeal to traditional value investors. |
| Dividend investor | Weak fit | Regencell does not pay a dividend and focuses on cash preservation for R&D. |
| Low-risk investor | Weak fit | High clinical, regulatory, and market risks make this an unsuitable choice for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The low float and speculative nature of the biotech industry lead to sharp price swings. |
| Valuation risk | High | Current valuations are often based on expectations rather than tangible financial performance. |
| Competition risk (Pharma competition) | High | Regencell competes against global giants with significantly deeper pockets and established regulatory track records. |
| Business quality | Medium | The business model is unproven at scale, making long-term sustainability difficult to predict. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | The successful development and commercialization of new medicine is fraught with failure points. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 15.39% | Avg. Invested days 9 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.06B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 213.8K shares | Beta 1.17 | 52 Weeks Range 4.51 - 69.00 | Updated Date 10/14/2026 |
52 Weeks Range 4.51 - 69.00 | Updated Date 10/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Sales of TCM-based liquid supplements and wellness formulations. | Revenue is highly volatile and dependent on success in niche health segments. |
| Geography | Concentrated presence in Asian markets with potential expansion plans. | Geographic concentration creates significant regional regulatory and market risk. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2.95B | Price to Sales(TTM) - |
Enterprise Value 2.95B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -44.58 | Shares Outstanding 495.88M | Shares Floating 55.62M |
Shares Outstanding 495.88M | Shares Floating 55.62M | ||
Percent Insiders 88.42 | Percent Institutions 0.29 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.